mRNA |
Vandetanib |
CTRPv2 |
pan-cancer |
AAC |
0.04 |
0.3 |
mRNA |
GSK4112 |
CTRPv2 |
pan-cancer |
AAC |
0.04 |
0.3 |
mRNA |
FQI-1 |
CTRPv2 |
pan-cancer |
AAC |
0.05 |
0.3 |
mRNA |
FGIN-1-27 |
CTRPv2 |
pan-cancer |
AAC |
-0.079 |
0.3 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.04 |
0.3 |
mRNA |
cabozantinib |
CTRPv2 |
pan-cancer |
AAC |
0.04 |
0.3 |
mRNA |
BRD-K97651142 |
CTRPv2 |
pan-cancer |
AAC |
0.041 |
0.3 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.035 |
0.3 |
mRNA |
WAY-362450 |
CTRPv2 |
pan-cancer |
AAC |
-0.04 |
0.3 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.032 |
0.3 |